StemLab will play an instrumental role in assisting with our accreditation and regulatory compliance needs and helping to grow our unique operations.
Vancouver, BC (PRWEB) October 24, 2013
STEMSOFT™ Software Inc (“STEMSOFT”), the leading provider of software solutions for the cell therapy and transplant community, is pleased to announce the licensing of StemLab™, the leading cell therapy transplant laboratory software, to TUMCells Interdisziplinäres Zentrum für zelluläre Therapien Technische Universität München (“TUMCells”) at the University Hospital Klinikum rechts der Isar in Germany.
“We are looking forward to realizing all the benefits an electronic workflow has to offer including heightened data integrity and integrated system checks,” said Prof. Martin Hildebrandt, Director TUMCells. “StemLab will play an instrumental role in assisting with our accreditation and regulatory compliance needs and helping to grow our unique operations.”
“The unique flexibility offered inside StemLab provides TUMCells with the robust platform they need to document and ensure manufacturing standardization for all their products,” states Nicole Waidman, Senior Director, Global Sales and Marketing for STEMSOFT. In addition, StemLab assists cell therapy laboratories with heightened quality control, a complete electronic batch record, built-in audit trails, improved inventory management, and the ability to generate robust outcome reports including ISBT 128 and Eurocet labels.
StemLab is currently used in over 65 cell therapy and cord blood banking laboratories worldwide. The system has been designed, and is continually updated, to meet the unique needs and accreditation requirements of the cell therapy market. StemLab comes complete with built-in industry standard workflows for HPC-C, HPC-A and HPC-M products to ease implementation resources and further promote standardization in this unique industry. For more information, visit http://www.stemsoft.com.